EyePoint (EYPT) Common Equity (2011 - 2026)
EyePoint (EYPT) posted Common Equity of $230.5 million for Q1 2026, down 24.71% sequentially from $306.1 million in Q4 2025, and down 22.76% YoY from $298.4 million in Q1 2025.
EyePoint (EYPT) Common Equity (2011 - 2026) Analysis & Trends
EyePoint has reported Common Equity for 16 years, with the latest figure at $230.5 million in Q1 2026.
- Quarterly Common Equity fell 22.76% year-over-year to $230.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $230.5 million (down 22.76% YoY) and the FY2025 annual result came in at $306.1 million, down 9.03% from the prior year.
- Common Equity declined to $230.5 million in Q1 2026 per EYPT's latest filing, from $306.1 million in the prior quarter.
- Over five years, Common Equity peaked at $336.5 million in Q4 2024 and troughed at $57.3 million in Q2 2023.
- A 5-year average of $195.7 million and a median of $218.7 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2024: Common Equity plunged 62.17% in 2023, then jumped 298.7% in 2024.
- Over 5 years, Common Equity stood at $96.4 million in 2022, then soared by 176.36% to $266.3 million in 2023, then grew by 26.35% to $336.5 million in 2024, then slipped by 9.03% to $306.1 million in 2025, then retreated by 24.71% to $230.5 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $230.5 million, $306.1 million, and $200.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | 166.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 166.41 Mn |
| Mar 31, 2026 | 230.47 Mn |
| Dec 31, 2025 | 306.11 Mn |
| Sep 30, 2025 | 200.18 Mn |
| Jun 30, 2025 | 246.01 Mn |
| Mar 31, 2025 | 298.40 Mn |
| Dec 31, 2024 | 336.50 Mn |
| Sep 30, 2024 | 218.73 Mn |
| Jun 30, 2024 | 228.31 Mn |
| Mar 31, 2024 | 249.93 Mn |
| Dec 31, 2023 | 266.32 Mn |
| Sep 30, 2023 | 58.62 Mn |
| Jun 30, 2023 | 57.26 Mn |
| Mar 31, 2023 | 78.39 Mn |
| Dec 31, 2022 | 96.37 Mn |
| Sep 30, 2022 | 136.35 Mn |
| Jun 30, 2022 | 151.37 Mn |
| Mar 31, 2022 | 166.82 Mn |
| Dec 31, 2021 | 184.38 Mn |
| Sep 30, 2021 | 92.75 Mn |